YCS-13292-97790
3 vaccinations
2 coded responses
31 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 980 / WA
- Registered
- 2021-05-06
- Relationship
- Self
- Race
- Asian
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-19
Dose 1 — Moderna
-
2021-05-06
Registered in v-safe
- 2021-05-06
- 2021-05-10
-
2021-05-17
Dose 2 — Moderna
-
2021-05-17
Health check-in — day 0, dose 2Feeling: Fair · Site: Pain · Chills, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-05-18
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
- 2021-05-19
- 2021-05-20
- 2021-05-21
- 2021-05-22
- 2021-05-23
- 2021-05-24
- 2021-06-02
- 2021-06-07
- 2021-06-14
- 2021-06-21
- 2021-06-28
- 2021-08-16
- 2021-11-15
-
2022-01-11
Dose 3 — Moderna
-
2022-01-12
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain, Swelling · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
-
2022-01-13
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Muscle or body achesAdult check-in
- 2022-01-15
- 2022-01-16
- 2022-01-17
- 2022-01-18
- 2022-01-25
- 2022-02-01
- 2022-02-08
- 2022-02-15
-
2022-02-22
Survey response — day 42, dose 3MedDRA: Rash, Urticaria — Feeling: Fair · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Hives and rashes occasionallyMedDRA releases: 2024-11 · check-in free text available
-
2022-02-22
Report sent to call center — day 42, dose 3Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-02-24
- 2022-04-12
- 2022-07-12
-
2023-01-11
Survey response — 12 months, dose 3MedDRA: COVID-19, Nasopharyngitis — Feeling: Good · Be unable to work or attend schoolMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-19 | Moderna | |
| 2 | 2021-05-17 | Moderna | |
| 3 | 2022-01-11 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-02-22 | Unsuccessful |
Free text
Release 11 — day 42, dose 3
Symptoms: Hives and rashes occasionally
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | COVID-19 | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Rash | · | · | ✓ |
| SD | Urticaria | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release